ABSTRACT
burden [2] . The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
STR and Adherence
Several national and international guidelines underscore the importance of simplifying antiretroviral (ARV) regimens. The Spanish guidelines suggest that switching to a STR in stable patients currently receiving 2 NRTIs and a PI and RTV offers added advantages in terms of treatment adherence and that the use of STRs is the most efficient strategy to prevent selective treatment non-adherence [3] , that is the possibility for a patient to consume less pills than those effectively prescribed. The Italian guidelines recommend the use of STRs and FDCs to improve durability of virologic suppression and to reduce the risk of developing resistance [4] . The European AIDS Clinical Society (EACS) guidelines recommend switching virologically suppressed patients for toxicity, to prevent long-term toxicity, and for simplification of a regimen. Therapeutic switches must always be performed within a context of known viral resistance and it must always be kept in mind that any drug combination has its toxicological profile and that by switching it, it is possible to replace one set of toxicities with another. Nevertheless, it has been shown that the performance of patients who switched to an STR compared to patients remaining on a more complex regimen is superior, both in terms of virological response and persistence [5, 6] . Patient adherence is a problem in any chronic illness. A review of 76 studies across a wide range of therapeutic areas that measured adherence using electronic monitoring has revealed that compliance rates in clinical trials are lower than previously assumed and that the number of prescribed doses per day is inversely related to compliance. According to electronic monitoring methods, the overall adherence rate was 71 ± 17%. Adherence to OD regimens was significantly higher than with 3-times-daily and 4-times-daily regimens, which reinforces the principle of simplicity [7] .
Decreased cART adherence is associated either with patient-related factors such as substance abuse, stress and depression, and with regimen-related factors. Regimen complexity includes the number of pills (pill burden), pill size, frequency and timing of doses, dietary and/or water requirements or restrictions, adverse events (AEs), medication storage requirements, number of prescriptions, number of copayments, refills, and medication bottles as well as the influence of these or other factors on the patient's lifestyle. Pill count, dosing frequency, and AEs have the greatest impact on patients' perceived ability to adhere to ARV medication regimens [8] . The exact rate of adherence necessary for cART treatment success is uncertain. Some studies indicate a minimum effective adherence rate of 80%, although a higher level (at least 95%) is considered ideal [9, 10] . More recent experience has shown that the relationship between treatment adherence and viral load suppression as well as resistance development can vary among drug classes [11] [12] [13] .
Several studies have shown that patients prefer OD regimens and simpler schedules [14] [15] [16] [17] [18] . A meta-analysis of 11 randomized, controlled trials on a total of 3029 subjects revealed that the adherence rate to cART was better with OD regimens, although the difference in adherence between OD and twice-daily (BID) regimens was modest (2.9%) Adherence is also a cornerstone of persistence. Persistence is the length of time patients remain on a specific ARV regimen and is a key tenet to achieve long-term treatment success. NNRTI-based regimens exhibited greater persistence than PI-based ones. Among the specific regimens, TDF/FTC/EFV provided the longest persistence [35] . As successive ARV regimens have exhibited progressively shorter durability, optimizing the duration of the first regimen in treatment-naïve patients is of utmost importance. OD regimens had greater longevity than those taken BID or more frequently and the shift to newer, more convenient and better-tolerated therapeutic options has induced, over the last few years, a remarkable increase in the durability of first regimens [36] . The switching boosted PI to rilpivirine (RPV) in combination with truvada as a STR (SPIRIT) study evaluated the switch from a PI-based cART to a STR (TDF/FTC/RPV) in chronically suppressed HIV patients. The study explored several patient-reported outcomes mostly dealing with symptoms often related to chronic therapies. After switching to STR, a general significant improvement of these symptoms was observed [6] .
Better adherence, higher QoL and patients' preferences are all key points which may combine to assure long-lasting efficacy of cART. In the COMPACT study [27] , the type of therapy also influenced the total cost of illness.
STR and Cost-Effectiveness
Patients treated with a STR showed association with the lowest cost. A selective non-adherence in a MPR of 3.5% increased the risk of hospitalization by 39% thus further increasing management costs. costs, corresponding to a € 4,541 lower costeffectiveness ratio per quality-adjusted life-years (QALY) [39] .
Similarly, the SPIRIT study showed that the use of the STR TDF/FTC/RPV was associated with an overall 16% cost reduction per subject through 24 weeks [6] .
Current STRs
Three These characteristics were further explored in a few small switch studies. In a larger controlled study in experienced patients, switching to TDF/FTC/RPV was noninferior to remaining on a PI/RTV ? 2NRTIs regimen with a lower rate of virological failure in the TDF/FTC/RPV arm. Mutations developed in \1% of subjects switched to TDF/FTC/RPV and after the switch an improvement in fasting lipids, including total cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides and total cholesterol/high-density lipoproteins (HDL) ratio was observed at week 24 and week 48 [6] . [60] . At week 144, the figures were 78% and 75% [56] . As for the previous study, the rate of discontinuation in the TDF/ FTC/COBI/EVG arm due to AEs was very low As for resistances, in the 102 study [51], 2% of patients in the TDF/FTC/COBI/EVG arm failed with resistance inducing mutations, usually to both NRTIs and EVG. The result was comparable to that observed in the TDF/FTC/ EFV arm. The integrase gene resistance mutations observed were E92Q, Q148R and N155H, which confer decreased susceptibility both to EVG and raltegravir and a potential lowlevel resistance to dolutegravir, and T66I, which preserves both raltegravir and dolutegravir (DTG).
Future Perspectives
An interesting STR that is anticipated is the combination ABC/3TC/DTG. Dolutegravir is an unboosted integrase inhibitor that has been effectively and safely used for the treatment of HIV-infected naïve (with 2 NRTIs) and experienced patients (with optimized background regimen) [57-59, 66, 67] , (Table 2) . DTG has shown to be effective with ABC/3TC or TDF/FTC regardless of blood level HIV-1 RNA [66] , although the number of patients on ABC/3TC with high viral load is limited. The efficacy of DTG has been compared to raltegravir in the SPRING-2 (NCT#01227824) study; both associated with 2 NRTIs in cARTnaïve patients: DTG 50 mg OD was as effective as raltegravir 400 mg BID at 96 weeks (81% vs. 76%). In the NRTI backbone comparison at 96 weeks those on DTG with ABC/3TC had efficacy rates of 74% compared to those on TDF/ FTC of 86%. [57] . DTG has also been compared to a boosted-PI, both associated with 2 NRTIs Virologic failure was observed in 2 patients (1%) on each arm without treatment-emergent resistance in either arm. The most common AEs were diarrhea with DRV/RTV and headache with DTG, while treatment-related study discontinuations were low (1% on DTG arm, 4% on DRV/RTV arm) [58] .
In the SINGLE (NCT#01263015) study, enrolling naïve patients, DTG 50 mg ? ABC/ 3TC had a better safety profile and was more effective through 48 weeks than TDF/FTC/EFV. The time to reach HIV-RNA \50 copies/mL was 28 days with DTG vs. 84 days with EFV (p\0.0001) and the increase in CD4 cells count was 267 with DTG vs. 208 with EFV (p\0.001). The main AEs observed in the DTG arm were insomnia and a mild, non-progressive increase in the serum creatinine without any effect on the actual glomerular filtration rate. Discontinuation due to AEs was observed in 10% of the patients in the EFV arm vs. 2% in the DTG arm and the higher discontinuation rate in the EFV arm drove the overall greater efficacy.
Moreover, in patients failing cART in the DTG arm, resistance to any of the regimen components did not develop [59] . The SINGLE study supported the idea of co-formulating ABC/3TC/DTG as a new promising STR whose limits might be related to the backbone: In the next few months, the patents of several relevant ARV drugs will expire and the possibility to combine bioequivalent drugs will become a reality, it has been hypothesized the possibility to obtain a fully bioequivalent STR combining ABC/3TC/EFV.
Limits of STRs in Clinical Practice
STRs, through regimen simplification, offer major advantages in the management of HIVpositive individual, but cannot be the answer to all problems. Intrinsic to the concept of STR are some potential limitations to their use.
STRs are based on FDCs not allowing, therefore, for dose adjustment of single components unless breaking the regimen to more pills. This may be the case in patients with impaired renal function in which the need to adjust specific drug dosages exist (e.g., 3TC; FTC; TDF) [44] . The same may be true to limit the occurrence of adverse effects in populations with genetic backgrounds that reduce the metabolic pathways of specific drugs (e.g., EFV) [71] .
A second limit may be the occurrence of intolerance as well as genetic predisposition to intolerance (e.g., HLAB*5701) to one of the components of the STR.
A third variable could be co-infections such as Hepatitis B that force clinicians to prefer, as far as possible, drugs able to control both HIV and hepatitis B virus (HBV) replication (FTC/ TDF and not 3TC/ABC) thus limiting the therapeutic options.
In deciding on the use of an STR, the clinician should pay attention to the resistance profile of any component of the STR itself remembering that transmitted resistance occurs mainly among NRTIs and NNRTIs [72, 73] , shows a steady prevalence trend (of about 10-12%) [73, 74] and is less frequent for newly developed compounds even if tested with high sensitivity methods [75] .
A further variable to consider are drug-drug kinetic interactions that may expose the risk of a functional dual therapy if blood concentrations of one of the STR components are reduced, this might be the case of RPV and proton pump inhibitors co-administration [76] or dolutegravir and antacids co-administration [77] . Polypharmacy is a growing problem in the aging HIV population and besides exposing to the risk of drug-drug interactions, polypharmacy may exert a non-specific negative effect by reducing adherence [78] and therefore, partially vanishing the advantages of STRs.
Finally, the cost of the newest compound, often higher than older ones, may constitute a drawback to the use of STRs, forcing national regulatory agencies to put limitations on their prescriptions [79] or ceilings to their use. 
